YahooSeptember 2, 2026 at 11:07 AM NY2 days ago
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo1 hour ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo1 hour ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo1 hour ago
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo1 hour ago
Radian (RDN) Up 1.5% Since Last Earnings Report: Can It Continue?
Yahoo1 hour ago